** Shares of Starpharma Holdings fall as much as 2.2% to A$0.091, their lowest level since Sept. 11
** Biopharmaceutical co withdraws marketing authorisation application for SPL7013 nasal spray with Australia's Therapeutic Goods Administration
** SPL7013 is an antiviral spray for protection against COVID-19
** Co says withdrawal after a more than three-year application and review process that consumed significant internal resources
** About 1.5 mln shares change hands, 3 times the 30-day avg of 478,000 shares
** Starpharma down 45.9% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。